Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A European Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

NCT02913456 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02913456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02913456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A European Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
November 16, 2016
Completion date
January 31, 2024
Enrollment
629 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer